Refinement of the conformation of a critical region of charge-charge interaction between cholecystokinin and its receptor

被引:41
作者
Ding, XQ
Pinon, DI
Furse, KE
Lybrand, TP
Miller, LJ
机构
[1] Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Dept Internal Med, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Dept Biochem & Mol Biol, Rochester, MN 55905 USA
[3] Vanderbilt Univ, Dept Chem, Nashville, TN USA
[4] Vanderbilt Univ, Ctr Struct Biol, Nashville, TN USA
关键词
D O I
10.1124/mol.61.5.1041
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Insight into the molecular basis of cholecystokinin (CCK) binding to its receptor has come from receptor mutagenesis and photoaffinity labeling studies, with both contributing to the current hypothesis that the acidic Tyr-sulfate-27 residue within the peptide is situated adjacent to basic Arg(197) in the second loop of the receptor. Here, we refine our understanding of this region of interaction by examining a structure-activity series of these positions within both ligand and receptor and by performing three-dimensional molecular modeling of key pairs of modified ligand and receptor constructs. The important roles of Arg(197) and Tyr-sulfate-27 were supported by the marked negative impact on binding and biological response with their natural partner molecule when the receptor residue was replaced by acidic Asp or Glu and when the peptide residue was replaced by basic Arg, Lys, p-amino-Phe, p-guanidino-Phe, or p-methylamino-Phe. Complementary ligand-receptor charge-exchange experiments were unable to regain the lost function. This was supported by the molecular modeling, which demonstrated that the charge-reversed double mutants could not form a good interaction without extensive rearrangement of receptor conformation. The models further predicted that R197D and R197E mutations would lead to conformational changes in the extracellular domain, and this was experimentally supported by data showing that these mutations decreased peptide agonist and antagonist binding and increased nonpeptidyl antagonist binding. These receptor constructs also had increased susceptibility to trypsin degradation relative to the wild-type receptor. In contrast, the relatively conservative R197K mutation had modest negative impact on peptide agonist binding, again consistent with the modeling demonstration of loss of a series of stabilizing inter- and intramolecular bonds. The strong correlation between predicted and experimental results support the reported refinement in the three-dimensional structure of the CCK-occupied receptor.
引用
收藏
页码:1041 / 1052
页数:12
相关论文
共 43 条
[11]  
Gigoux V, 1999, PROTEIN SCI, V8, P2347
[12]   Arginine 336 and asparagine 333 of the human cholecystokinin-A receptor binding site interact with the penultimate aspartic acid and the C-terminal amide of cholecystokinin [J].
Gigoux, V ;
Escrieut, C ;
Fehrentz, JA ;
Poirot, S ;
Maigret, B ;
Moroder, L ;
Gully, D ;
Martinez, J ;
Vaysse, N ;
Fourmy, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (29) :20457-20464
[13]   Essential role of extracellular charged residues of the human CCK1 receptor for interactions with SR 146131, SR 27897 and CCK-8S [J].
Gouldson, P ;
Legoux, P ;
Carillon, C ;
Dumont, X ;
Le Fur, G ;
Ferrara, P ;
Shire, D .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 389 (2-3) :115-124
[14]  
GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440
[15]   A peptide agonist acts by occupation of a monomeric G protein-coupled receptor: Dual sites of covalent attachment to domains near TM1 and TM7 of the same molecule make biologically significant domain-swapped dimerization unlikely [J].
Hadac, EM ;
Ji, ZS ;
Pinon, DI ;
Henne, RM ;
Lybrand, TP ;
Miller, LJ .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (12) :2105-2111
[16]   Direct identification of a second distinct site of contact between cholecystokinin and its receptor [J].
Hadac, EM ;
Pinon, DI ;
Ji, ZS ;
Holicky, EL ;
Henne, RM ;
Lybrand, TP ;
Miller, LJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (21) :12988-12993
[17]   Relationship between native and recombinant cholecystokinin receptors: Role of differential glycosylation [J].
Hadac, EM ;
Ghanekar, DV ;
Holicky, EL ;
Pinon, DI ;
Dougherty, RW ;
Miller, LJ .
PANCREAS, 1996, 13 (02) :130-139
[18]  
HUANG S, 1994, J BIOL CHEM, V269, P26121
[19]   Direct identification of a distinct site of interaction between the carboxyl-terminal residue of cholecystokinin and the type A cholecystokinin receptor using photoaffinity labeling [J].
Ji, ZS ;
Hadac, EM ;
Henne, RM ;
Patel, SA ;
Lybrand, TP ;
Miller, LJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (39) :24393-24401
[20]   Identification of two amine acids of the human cholecystokinin-A receptor that interact with the N-terminal moiety of cholecystokinin [J].
Kennedy, K ;
Gigoux, V ;
Escrieut, C ;
Maigret, B ;
Martinez, J ;
Moroder, L ;
Frehel, D ;
Gully, D ;
Vaysse, N ;
Fourmy, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (05) :2920-2926